Evolocumab is named as a drug or biological intervention in 12 clinical trials in our China and USA trial registers, 8 of which are recruiting. Lead sponsors include General Hospital of Shenyang Military Region (2), Yun Dai Chen (2) and Amgen (1). Registered phases: Phase 4, Not applicable, Observational, Phase 2/3 and Phase 2. Conditions studied include Acute Myocardial Infarction; Cardiovascular Disease; Myocardial Infarction.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Acute Myocardial Infarction | 2 |
| Cardiovascular Disease | 1 |
| Myocardial Infarction | 1 |
| Stroke | 1 |
| Coronary Revascularization | 1 |
| Hypertriglyceridemia Induced Acute Pancreatitis | 1 |
| Coronary | 1 |
| Coronary Artery Disease | 1 |
| Acute Ischemic Stroke | 1 |
| Hypercholesterolemia | 1 |
| Intracranial Artery Stenosis | 1 |
| Stroke, Ischemic | 1 |
| Atherosclerosis, Cerebral | 1 |
| Myocardial Ischaemic Syndrome | 1 |
| Coronary Heart Disease | 1 |
| Ischemic Stroke | 1 |
| Large-Artery Atherosclerosis (Embolus/Thrombosis) | 1 |
| Acute Coronary Syndromes | 1 |
| Lead sponsor | Trials |
|---|---|
| General Hospital of Shenyang Military Region | 2 |
| Yun Dai Chen | 2 |
| Amgen | 1 |
| West China Hospital | 1 |
| Nanfang Hospital, Southern Medical University | 1 |
| Regeneron Pharmaceuticals | 1 |
| Shanghai Tong Ren Hospital | 1 |
| Nanjing First Hospital, Nanjing Medical University | 1 |
| Nanjing Medical University | 1 |
| Tongji Hospital | 1 |
| Register | Evolocumab trials |
|---|---|
| Clinical trials in China | 10 |
| Clinical trials in USA | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Evolocumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Evolocumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.